

Serial No.: 10/532956
Group Art Unit No.: 1624

Amendments to the Claims:

1. (Currently Amended): {A compound} selected from the group consisting of:
N-[4-chloro-2-hydroxy-3-(4-methyl-piperazine-1-sulfonyl)-phenyl]-N'-(2-chloro-3-fluorophenyl)urea;
N-[4-chloro-2-hydroxy-3-(4-(2-hydroxyethyl)-piperazine-1-sulfonyl)phenyl]-N'-(2-chloro-3-fluorophenyl)urea; and
N-[4-chloro-2-hydroxy-3-(1-piperazinylsulfonyl)phenyl]-N'-(2-chloro-3-fluorophenyl)urea or a pharmaceutically acceptable salt thereof.
2. (Original): A pharmaceutical composition comprising a compound according to Claim 1 and a pharmaceutically acceptable carrier or diluent.
3. (Currently Amended): A method of treating a chemokine mediated disease, wherein the chemokine binds to an IL-8 a or b receptor in a mammal, which method comprises administering to said mammal an effective amount of a compound according to Claim 1, wherein the disease is selected from the group consisting of asthma, chronic obstructive pulmonary disease and adult respiratory distress syndrome.
4. (Canceled)
5. (New): A method according to claim 3 wherein the disease is chronic obstructive pulmonary disease.